RDP Pharma: Analyzing cervical biofluids without invasive biopsies

Wednesday, October 15, 2025 @ 12:00 am

Researchers from Valdospan GmbH, a subsidiary of RDP Pharma AG, in collaboration with the Department of Gynecology and Obstetrics at Karl Landsteiner University of Health Sciences in Tulln have published a groundbreaking study demonstrating the potential of multicolor flow cytometry for noninvasive profiling of cervical cell populations.

The peer-reviewed article, titled “Noninvasive Cell Population Profiling of Normal and Dysplastic Cervical Biofluids by Multicolor Flow Cytometry as a Promising Tool for Companion Diagnostics,” was published in Cancers (2025, 17(20), 3328.

Authored by Christoph Berger, Wolf Dietrich, Manuela Richter, Florian Kellner, Christian Kühne, and Katharina Strasser, the study highlights how advanced flow cytometry can be applied to routine cervical screening samples to identify cellular and immunological signatures associated with normal and dysplastic conditions.

“Our results demonstrate that cervical biofluids contain valuable information that can be analyzed without invasive biopsies,” said Dr. Katharina Strasser, lead author and Deputy Head of Biology Department at Valdospan GmbH. “This approach opens up exciting possibilities for personalized diagnostics and for guiding targeted therapies in women’s health.”

The research represents a significant step toward developing companion diagnostic tools that support precision medicine in gynecologic oncology. By leveraging noninvasive sampling and high-dimensional flow cytometry, this method could complement existing cytology and HPV testing — providing deeper insights into cellular immune landscapes and disease progression.

This publication underscores RDP Pharma’s commitment to advancing innovative diagnostic platforms that enable early detection, patient stratification, and treatment monitoring through cutting-edge cell analysis technologies.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Curatis valuation report: Epidemiology data reveal vast potential

November 24, 2025

BC Platforms launches first-to-market AI-native analytics product that accelerates precision medicine

Proprietary agentic AI model transforms genomic and real-world data into actionable insights across the full drug lifecycle Enables faster development of breakthrough therapies, including tumor-agnostic cancer treatments, through a 360-degree view of the precision medicine landscape Empowers scientific researchers across the life sciences and healthcare continuum to perform large-scale data analys
November 18, 2025

Pharvaris: Third quarter 2025 financial results

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictibant
November 12, 2025

Molecular Partners: First human images from targeting radiotherapy

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2
November 12, 2025

InSphero acquires DOPPL SA for 3D in vitro drug models

InSphero AG is acquiring DOPPL SA to create the most comprehensive 3D in vitro model portfolio, combining scalable spheroid and organoid technologies for next-generation drug discovery and safety testing.
November 11, 2025